Total Funding
83
60
Total FundingSeries B raised
Growth Score
-2 pts
Heat Score
10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
128361
IMB Dx is a precision oncology firm committed to advancing safe and accurate cancer diagnosis, monitoring, and screening.
- Duhee Bang: Co-founder
- Tae You Kim: CEO & Co-founder
About the Company
IMB Dx is a precision oncology company that develops minimally invasive liquid biopsy tests for safe & affordable cancer diagnosis and monitoring. Our liquid biopsy platform, AlphaLiquid®, is designed for early & advanced cancer patients to enable accurate tumor profiling, therapy selection, recurrence monitoring, and early cancer
detection. Our proprietary technology detects and analyzes trace amounts of circulating tumor DNA (ctDNA) from a single draw of blood. We are committed to providing useful information for patients and physicians and to revolutionizing the way cancer is diagnosed, monitored, and treated.
